ArticleGeroScience2020
Human geroprotector discovery by targeting the converging subnetworks of aging and age-related diseases.
Article in GeroScience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Foundations of Gerophysics.Aging · 2026Article
- Integrating evolutionary theory into a framework for the mechanistic evaluation of candidate anti-aging interventions.Frontiers in aging · 2026Article
- MVSGDR: multi-view stacked graph convolutional network for drug repositioning.Briefings in bioinformatics · 2025Article
- Natural polyphenols as novel interventions for aging and age-related diseases: Exploring efficacy, mechanisms of action and implications for future research.Chinese herbal medicines · 2025Review
- Prediction of drug target interaction based on under sampling strategy and random forest algorithm.PloS one · 2025Article
- Protein structure prediction via deep learning: an in-depth review.Frontiers in pharmacology · 2025Review
- Editorial: Bioinformatics analysis of single cell sequencing and multi-omics in the aging and age-associated diseases.Frontiers in aging neuroscience · 2024Article
- DLC-ac4C: A Prediction Model for N4-acetylcytidine Sites in Human mRNA Based on DenseNet and Bidirectional LSTM Methods.Current genomics · 2023Article
- An Autophagy-Associated Prognostic Gene Signature for Breast Cancer.Biochemical genetics · 2023Article
- MNNMDA: Predicting human microbe-disease association via a method to minimize matrix nuclear norm.Computational and structural biotechnology journal · 2023Article
- Article
- CNNLSTMac4CPred: A Hybrid Model for N4-Acetylcytidine Prediction.Interdisciplinary sciences, computational life sciences · 2022Article
- A Prognostic Ferroptosis-Related lncRNA Model Associated With Immune Infiltration in Colon Cancer.Frontiers in genetics · 2022Article
- Circulating Tumor Cell Identification Based on Deep Learning.Frontiers in oncology · 2022Article
- Plasma Exosomes Transfer miR-885-3p Targeting the AKT/NFκB Signaling Pathway to Improve the Sensitivity of Intravenous Glucocorticoid Therapy Against Graves Ophthalmopathy.Frontiers in immunology · 2022Article
- Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion.Frontiers in microbiology · 2022Article
- Identification of Novel Immune Ferropotosis-Related Genes Associated With Clinical and Prognostic Features in Gastric Cancer.Frontiers in oncology · 2022Article
- Prediction of Tumor Mutation Load in Colorectal Cancer Histopathological Images Based on Deep Learning.Frontiers in oncology · 2022Article
- Lung Cancer Stage Prediction Using Multi-Omics Data.Computational and mathematical methods in medicine · 2022Article
- Ultrasound Image Classification of Thyroid Nodules Based on Deep Learning.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A key goal of geroscience research is to identify effective interventions to extend human healthspan, the years of healthy life. Currently, majority of the geroprotectors are found by screening compounds in model organisms; whether they will be effective in humans is largely unknown. Here we present a new strategy called ANDRU (aging network based drug discovery) to help the discovery of human geroprotectors. It first identifies human aging subnetworks that putatively function at the interface between aging and age-related diseases; it then screens for pharmacological interventions that may "reverse" the age-associated transcriptional changes occurred in these subnetworks. We applied ANDRU to human adipose gene expression data from the Genotype Tissue Expression (GTEx) project. For the top 31 identified compounds, 19 of them showed at least some evidence supporting their function in improving metabolic traits or lifespan, which include type 2 diabetes drugs such as pioglitazone. As the query aging genes were refined to the ones with more intimate links to diseases, ANDRU identified more meaningful drug hits than the general approach without considering the underlying network structures. In summary, ANDRU represents a promising human data-driven strategy that may speed up the discovery of interventions to extend human healthspan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.